Top Page
60 Degrees Pharmaceuticals, Inc.
(NASDAQ:SXTP)
60 Degrees Pharmaceuticals, Inc. (SXTP) vs. SPDR S&P 500 ETF (SPY)
60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model
60 Degrees Pharmaceuticals, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 960.89K | 681.35K | 253.57K | 223.21K | 1.16M | 2.55M |
| Gross Profit | 277.54K | 222.81K | -220.98K | -209.16K | 309.60K | 1.48M |
| EBITDA | -7.64M | -7.88M | -1.43M | -2.11M | -1.01M | -341.17K |
| Net Income | -7.80M | -7.95M | -3.77M | -6.18M | -4.25M | -3.03M |
Balance Sheet | ||||||
| Total Assets | 4.18M | 5.76M | 7.78M | 1.30M | 1.39M | 2.61M |
| Cash, Cash Equivalents and Short-Term Investments | 1.97M | 3.39M | 2.14M | 264.87K | 115.40K | 191.70K |
| Total Debt | 154.25K | 155.89K | 172.67K | 22.42M | 18.80M | 19.14M |
| Total Liabilities | 1.84M | 1.80M | 2.99M | 25.45M | 19.55M | 20.68M |
| Stockholders Equity | 2.43M | 4.04M | 4.87M | -23.58M | -17.58M | -17.50M |
Cash Flow | ||||||
| Free Cash Flow | -3.36M | -5.83M | -4.66M | -1.07M | -684.50K | -238.28K |
| Operating Cash Flow | -3.32M | -5.65M | -4.54M | -1.01M | -649.11K | -167.30K |
| Investing Cash Flow | -97.91K | -1.89M | -115.89K | -60.13K | -35.39K | -70.98K |
| Financing Cash Flow | 6.85M | 7.05M | 6.47M | 1.22M | 611.23K | 277.36K |
60 Degrees Pharmaceuticals, Inc. Technical Analysis
60 Degrees Pharmaceuticals, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $5.17M | -0.11 | -285.78% | ― | 120.67% | -456.33% | |
33 Underperform | $4.76M | >-0.01 | -254.09% | ― | -9.34% | 93.84% | |
31 Underperform | $5.28M | -0.11 | -708.34% | ― | ― | 51.27% | |
29 Underperform | $4.66M | -0.04 | -168.95% | ― | ― | 90.27% |
60 Degrees Pharmaceuticals, Inc. Corporate Events
Study Overview: The B-FREE Chronic Babesiosis Study, officially titled B-FREE Chronic Babesiosis Study: A Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients With Severe Fatigue, aims to evaluate the efficacy of Tafenoquine in treating chronic babesiosis, particularly in patients suffering from severe fatigue. This study is significant as it addresses a debilitating condition with limited treatment options.
On October 8, 2025, 60 Degrees Pharmaceuticals, Inc. held its virtual 2025 Annual Stockholders Meeting, where various proposals were voted on by the shareholders. The meeting saw the election of five directors, approval of an amendment to increase shares in the 2022 Equity Incentive Plan, a reverse stock split, and the ratification of RBSM LLP as the accounting firm for 2025, all of which were approved.
The most recent analyst rating on (SXTP) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
On September 9, 2025, 60 Degrees Pharmaceuticals, Inc. presented investor information highlighting the potential growth of ARAKODA, especially for chronic babesiosis, which could surpass its use for malaria prevention. The company faces challenges such as low brand recognition and competition from generic alternatives, but aims to address these through a commercial pilot program to increase awareness and differentiate ARAKODA in the market.
The most recent analyst rating on (SXTP) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. entered into an At-The-Market Sales Agreement with H.C. Wainwright & Co., LLC to offer and sell shares of its common stock, potentially raising up to $1,397,533. The agreement allows the company flexibility in selling shares while Wainwright acts as the sales agent, earning a 3% commission on sales. Additionally, on the same date, the company terminated a previous sales agreement with Wallachbeth Capital LLC, effective immediately, releasing both parties from any obligations.
The most recent analyst rating on (SXTP) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and marketing new medicines for infectious diseases, with its headquarters in Washington, D.C. The company recently released its earnings report for the second quarter of 2025, highlighting a continued focus on its lead product, ARAKODA®, for malaria prevention, and ongoing development programs for other diseases. Despite a net loss of $1.73 million for the quarter, the company reported a gross profit increase to $50,881, driven by a rise in research revenues. Operating expenses remained high at $1.86 million, primarily due to research and development and general administrative costs. Looking ahead, 60 Degrees Pharmaceuticals plans to continue its efforts to achieve profitability through additional capital raising and strategic initiatives, while addressing the challenges of the competitive biopharmaceutical industry.